Search
Felbamate
go.drugbank.com/drugs/DB00949ApprovedFelbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat par...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsIsoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 SubstratesNorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigationalNorgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with eth...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythm...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsZaleplon
go.drugbank.com/drugs/DB00962ApprovedIllicitZaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesCinacalcet
go.drugbank.com/drugs/DB01012ApprovedInvestigationalCinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesClobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigationalClobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the liter...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A SubstratesMethoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates